Neurohormonal Parameters in Hypertrophic Cardiomyopathies

Evaluation at Rest and Exercise of Clinical, Ultrasonic and Neurohormonal Parameters in Hypertrophic Cardiomyopathies

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01729702

Acronym

REEF-CMH

Enrollment

131

Registered

2012-11-20

Start date

2009-04-30

Completion date

2013-12-31

Last updated

2014-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

1- Primary (Sarcomeric) Hypertrophic Cardiomyopathy, 2- Obstructive Hypertrophic Cardiomyopathy, 3- Non Obstructive Hypertrophic Cardiomyopathy

Keywords

1- Hypertrophic cardiomyopathy, 2- BNP, 3- NT-proBNP, 4- Neurohormons

Brief summary

The primary purpose of this study is to demonstrate that changes in plasma levels of circulating neurohormones (mainly BNP and NT-proBNP), measured at rest and post-exercise correlate with exercise functional limitation (assessed by exercise peak VO2) and exercise ultrasonic parameters (as left ventricular filling, obstruction, and mitral regurgitation)

Detailed description

The secondary purposes are to study the kinetics of secretions of natriuretic peptides, and their relationships with extent of MRI myocardial fibrosis with the degree of exercise functional limitation.

Interventions

OTHERblood sample collection

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* \- Age 18 to 75 years * Primary (sarcomeric) hypertrophic cardiomyopathy, obstructive or non obstructive, with studies of exercise peak oxygen consumption and cardiac MRI with gadolinium late-enhancement * Informed consent * Patient with a social insurance Patient at rest * \- Age 18 to 75 years * Primary (sarcomeric) hypertrophic cardiomyopathy, obstructive or non obstructive * Informed consent * Patient with a social insurance

Exclusion criteria

* \- Insufficient echogenicity * Permanent atrial fibrillation * Complete BBB on the ECG * LVEF \< 35 % * Previous septal ablation (surgical or percutaneous) * Simultaneous participation to another biomedical research If exercise needed: * contraindication to exercise : hemodynamic instability, uncontrolled high blood pressure (\>220/120 mmHg), severe aortic stenosis * Inability to exercise (muscular, pulmonary, elderly patient)

Design outcomes

Primary

Measure	Time frame
Plasmatic Neurohormonal measures: BNP - NT ProBNP - Troponine	Day 1 at rest and during exercise

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026